Compare Mattel Inc (MAT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Novartis AG — how do they compare? Mattel Inc trades at $15.05 (market cap $4.21B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 70.8× Mattel Inc's market cap, and Novartis AG pays a 3.02% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| MAT | NVS | |
|---|---|---|
Market Cap | $4.21B | $298.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $168.62 |
52-Week Low | $13.05 | $118.55 |
Enterprise Value | $6.44B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $14.79, up 2.07% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with revenue growth of 10% but an earnings miss due to higher costs. Valuation appears reasonable with P/E of 11.03 and P/S of 0.82, while profitability metrics show strong ROE of 20.5% despite margin pressures from increased advertising expenses.
The stock presents a balanced opportunity with analyst consensus leaning bullish (53% buy ratings) but faces near-term headwinds from cost inflation and discretionary spending pressures. Long-term growth drivers include toy-based entertainment partnerships and digital gaming expansion, though execution risks and market volatility require careful monitoring.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
